Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-15
2009-08-11
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S388230
Reexamination Certificate
active
07572766
ABSTRACT:
The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
REFERENCES:
patent: 5019393 (1991-05-01), Ito et al.
patent: 5217492 (1993-06-01), Guire et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5635482 (1997-06-01), Bhatnagar
patent: 5747334 (1998-05-01), Kay et al.
patent: 5866363 (1999-02-01), Pieczenik
patent: 5892020 (1999-04-01), Mezes et al.
patent: 6117632 (2000-09-01), O'Mahoney
patent: 6235716 (2001-05-01), Ben-Sasson
patent: 6280760 (2001-08-01), Meyer et al.
patent: 6294353 (2001-09-01), Pack et al.
patent: 6428579 (2002-08-01), Valentini
patent: 6780582 (2004-08-01), Wagner et al.
patent: 6821528 (2004-11-01), Scott
patent: 2002/0037853 (2002-03-01), Bhatnagar
patent: 2002/0049495 (2002-04-01), Kutryk et al.
patent: 2003/0060408 (2003-03-01), Bar-Or
patent: 2003/0114552 (2003-06-01), Schacht
patent: 2003/0161809 (2003-08-01), Houston et al.
patent: 2003/0203038 (2003-10-01), Vail
patent: 2003/0219429 (2003-11-01), Budny
patent: 2003/0229393 (2003-12-01), Kutryk et al.
patent: 2004/0127640 (2004-07-01), Belcher et al.
patent: 2005/0085623 (2005-04-01), Balian
patent: 2005/0187162 (2005-08-01), Dhanaraj
patent: WO 98/13478 (1998-04-01), None
patent: WO 02/100426 (2002-12-01), None
patent: WO/03/014145 (2003-02-01), None
patent: WO 03/072542 (2003-09-01), None
Keogh, J.R., and J.W. Eaton, “Albumin Binding Surfaces for Biomaterials,”J. Lab Clin Med., Oct. 1994, pp. 537-545, vol. 124, No. 4 (Abstract).
Harris, L.G., et al., “Staphylococcus aureusAdhesion to Titanium Oxide Surfaces Coated with Non-Functionalized and Peptide-Functionalized Poly(L-lysine)-Grafted-Poly(Ethylene Glycol) Copolymers,”Biomaterials, 2004, pp. 4135-4148, vol. 25.
Issack, P.S. and P.E. Dicesare, “Recent Advances Toward the Clinical application of Bone Morphogenetic Proteins in Bone and Cartilage Repair,”The American Journal of Orthopedics, Sep. 2003, pp. 429-436.
Lin, T.-L., et al., “Antimicrobial Coatings: A Remedy for Medical Device-Related Infections,”Medical Device Technology, Oct. 2001.
Sato, A.K., et al., “Development of Mammalian Serum Albumin Affinity Purification Media by Peptide Phage Display,”Biotechnol. Prog., 2002, pp. 182-192, vol. 18.
Sykaras, N., and L.A. Opperman, “Bone Morphogenetic Proteins (BMPs): How Do They Function and What Can They Offer the Clinician,”Journal of Oral Science, 2003, pp. 57-73, vol. 45, No. 2.
Wagner, V.E., et al., “Protein and Bacterial Fouling Characteristics of Peptide and Antibody decorated Surfaces of PEG-poly (Acrylic Acid) Co-Polymers,”Biomaterials, 2004, pp. 2247-2363, vol. 25.
Zasloff, M., “Antimicrobial Peptides of Multicellular Organisms,”Nature, Jan. 24, 2002, pp. 389-395, vol. 415.
Amin, A.R., “Type II Interleukin-1β Receptor: A Candidate for Gene Therapy in Human Arthritis”,Clinical Orthopaedics and Related Research, 2000, pp. S179-S188, vol. No. S379.
Arai, Y, et al., “Gene Delivery to Human Chondrocytes by an Adeno Associated Virus Vector”,The Journal of Rheumatology, 2000, pp. 979-982, vol. 27(4).
Bakker, A.C., et al., “Prevention of Murine Collagen-Induced Arthritis in the Knee and Ipsilateral Paw by Local Expression of Human Interleukin-1 Receptor Antagonist Protein in the Knee”,Arthritis and Rheumatism, 1997, pp. 893-900, vol. 40(5).
Baragi, V.M., et al., “Transplantation of Transduced Chondrocytes Protects Articular Cartilage from Interleukin 1-Induced Extracellular Matrix Degradation”,Journal of Clinical Investigation, 1995, pp. 2454-2460, vol. 96.
Brower-Toland, B.D., et al., “Direct Adenovirus-Mediated Insulin-Like Growth Factor I Gene Transfer Enhances Transplant Chondrocyte Function”,Human Gene Therapy, 2001, pp. 117-129, vol. 12.
Chikana, I.C. and Fernandes, L., “Novel Strategies for the Treatment Of Osteoarthritis”,Exp. Opin. Invest. Drugs, 200, pp. 1499-1510, vol. 9(10).
Doherty, P.J., et al., “Resurfacing of Articular Cartilage Explants with Gebetically-Modified Human Chondrocytes in vitro”,Osteoarthritis and Cartilage, 1998, pp. 153-160, vol. 6.
Doherty, P.J., et al., “Adhesion of Transplanted Chondrocytes onto Cartilage in vitro and in vivo”,Journal of Rheumatology, 2000, pp. 1725-1731, vol. 27(7).
Evans, C.H., et al. , “Using Gene Therapy to Protect and Restore Cartilage”,Clinical Orthopaedics and Related Research, 2000, pp. S214-S219, vol. No. 379S.
Goomer, R.S., et al., “High-Efficiency Non-Viral Transfection of Primary Chondrocytes and Perichondrial Cells for ex-vivo Gene Therapy to Repair Articular Cartilage Defects”,Osteoarthritis and Cartilage, 2001, pp. 248-256, vol. 9.
Grunkemeier, J.M. and Horbett, T.A., “Fibrinogen Adsorption to Receptor-Like Biomaterials Made by Pre-Adsorbing Peptides to Polystyrene Substrates”,Journal of Molecular Recognition, 1996, pp. 247-257, vol. 9.
Hall, F.L., et al., “Phenotypic Differentiation of TGF-β1-Responsive Pluripotent Premesenchymal Prehematopoietic Progenitor (P4 Stem) Cells from Murine Bone Marrow”,Journal of Hematology&Stem Cell Research, 2001, pp. 261-271, vol. 10.
Knezevic, I., et al., “Direct Binding of the Platelet Integrin αIIbβ3(GPIIb-IIIa) to Talin: Evidence that Interaction is Mediated through the Cytoplasmic Domains of Both αIIband β3”,The Journal of Biological Chemistry, 1996, pp. 16416-16421, vol. 271(27).
Kubo, T., et al., “Expression of Transduced HSP70 Gene Products Chondrocytes from Stress”,Journal of Rheumatology, 2001, pp. 330-335, vol. 28(2).
Liechty, K.W., et al., “Human Mesenchymal Stem Cell Engraft and Demonstrate Site-Specific Differentiation After in utero Transplantation in Sheep”,Nature Medicine, 2000, pp. 1282-1286, vol. 6(11).
Madry, H., et al., “Overexpression of Human Insulin-Like Growth Factor-I Promotes New Tissue Formation in an ex vivo Model Of Articular Chonrocyte Transplantation”,Gene Therapy, 2001, pp. 1443-1449, vol. 8.
Malemud, C.J and Goldberg, V.M., “Future Directions for Research and Treatment of Osteoarthritis”,Frontiers in Bioscience, 1999, pp. 762-771, vol. 4.
Malinda, K.M., et al., “Identification of Laminin α1 and β1 Chain Peptides Active for Endothelial Cell Adhesion, Tube Formation, and Aortic Sprouting”,The FASEB Journal, 1999, pp. 53-62, vol. 13.
Martinek, V., et al., “Treatment of Osteochondral Injuries”,Clinics in Sports Medicine, 2001, pp. 403-416, vol. 20(2).
Nixon, A.J., et al. , “Insulinlike Growth Factor-I Gene Therapy Applications for Cartilage Repair”,Clinical Orthopaedics and Related Research, 2000, pp. S201-S213, vol. No. 379S.
Nomizu, M., et al., “Active Peptides from the Carboxyl-Terminal Globular Domain of Laminin A2 andDrosophhilaA Chains”,FEBS Letters, 1996, pp. 37-42, vol. 396.
Nomizu, M., et al., “Cell Binding Sequences in Mouse Laminin α1 Chains”,The Journal of Biological Chemistry, 1998, pp. 32491-32499, vol. 273(46).
Nomizu, M., et al., “Identification of Cell Binding Sequences in Mouse Laminin γ1 Chain by Systematic Papetide Screening”,
Benson Ray Edward
Beyer, Jr. Wayne F.
Hamilton Paul T.
Hyde-DeRuyscher Robin
Affinergy, Inc.
Carlson Karen Cochrane
Kiefer Laura L.
Nelson M. Bud
LandOfFree
IFBMs to promote the specific attachment of target analytes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IFBMs to promote the specific attachment of target analytes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IFBMs to promote the specific attachment of target analytes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084536